Coronavirus company news summary – Parexel and Synairgen sign partnership for Covid-19 drugs – EIB invests into Immunic’s Covid-19 drug

21 October 2020 (Last Updated October 21st, 2020 12:01)

21 October 2020

The European Investment Bank (EIB) and Immunic have signed a financial agreement to back the development of a Phase II CALVID-1 trial of IMU-838 drug for Covid-19. IMU-838 is an orally available small molecule that has shown positive results against the SARs-CoV-2 infection among patients suffering from moderate symptoms. IMU-838 is also being evaluated for the treatment of other diseases.

Parexel has collaborated with Synairgen to carry out the latter's Phase III study of SNG001, an inhaled formulation of IFN-beta-1a, to treat Covid-19 patients. The study will enrol 900 patients spanning 20 countries and will evaluate the role of SNG001 in the recovery of patients receiving oxygen.

CytoDyn has announced that it has received Data Safety Monitoring Committee (DSMC) recommendations after an interim analysis of its Phase IIb/III registrational trial among severely affected and critical Covid-19 patients. The DSMC encouraged the study to be continued and requested for additional data when enrolment reached 293 patients.

Samsung Biologics has signed a partnership agreement with Dinona for the further expansion of its contract design organisation proficiencies to provide the complete possibilities of its development services. As per the partnership, the companies will collaborate to speed up the development of DNP-019, an antibody therapy to fight Covid-19.